Comparative Risk of Thrombotic and Cardiovascular Events with Tofacitinib and Anti-TNF Agents in Patients with Inflammatory Bowel Diseases.
Bharati D KocharDavid ChengTianxi CaiAshwin N AnanthakrishnanPublished in: Digestive diseases and sciences (2022)
In this large, active comparator, study, we demonstrate that tofacitinib was not associated with a higher risk of adverse thrombotic events compared with anti-TNFs in patients with IBD.